Updated ESMO Guidelines for Metastatic Colorectal Cancer
The European Society for Medical Oncology (ESMO) has released updated clinical guidelines for managing metastatic colorectal cancer. The new framework incorporates advanced molecular profiling and specific therapeutic algorithms to improve patient outcomes.
Why it matters
These guidelines standardize evidence-based care for a complex disease, directly influencing treatment protocols for oncologists globally.
Gustave Roussy Research shared on LinkedIn :
“Updated ESMO Clinical Practice Guidelines deliver a refined framework for the multidisciplinary management of metastatic colorectal cancer.
Managing metastatic colorectal cancer (mCRC) requires navigating an increasingly complex landscape of molecular biomarkers, targeted therapies and evolving locoregional strategies. Standardizing evidence-based care across diverse clinical scenarios remains essential to optimize patient outcomes.
Published in Annals of Oncology on behalf of the ESMO Guidelines Committee , the updated guideline co-authored by Michel Ducreux (Gustave Roussy) establishes structured therapeutic algorithms driven by MMR/MSI status, ECOG performance status, primary tumour location and extended molecular profiling ( RAS, BRAF, HER2, KRAS G12C ).
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in